Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NLRP3修飾因子
Document Type and Number:
Japanese Patent JP7104633
Kind Code:
B2
Abstract:
This disclosure features compounds of Formula I, or a pharmaceutically acceptable salt thereof:in which R1, R2, R3, and R4 are as defined herein. These compounds are modulators of NLRP3, which are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Inventors:
Gary Glick
Shomil Gosh
William Earl Rauch
Edward James Olhaba
Application Number:
JP2018554782A
Publication Date:
July 21, 2022
Filing Date:
April 19, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Innate Tumor Immunity, Inc.
International Classes:
C07D471/04; A61K31/4745; A61K31/496; A61K31/506; A61K31/5377; A61K45/00; A61P35/00; A61P35/02; A61P43/00; C07D519/00
Domestic Patent References:
JP3027380A
Foreign References:
WO2005123079A2
WO2006091394A2
WO2005020999A1
US5389640
WO2006009832A1
WO2006098852A2
WO2005123080A2
US20090069314
WO2016004876A1
US20090054476
Other References:
CAS REGISTRY NO. 1027225-83-7,DATABASE REGISTRY, [Online] ,2008年06月11日,[2021年 1月18日検索], Retrieved from: STN
FOSSA, P et al.,New pyrazolo[3,4-b]pyridones as selective A1 adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies,Organic & Biomolecular Chemistry,2005年,Vol. 3,pp. 2262-2270
Attorney, Agent or Firm:
Yamato Kento
Shinagawa
Wu Yingyan
Futami Kamahira
Masahiro Suwon